The classical vs nonclassical NSAIDs: can the reduction in pain overcome the thrombotic risk? (Q36953015)

17 August 2017

1 reference

title

The classical vs nonclassical NSAIDs: can the reduction in pain overcome the thrombotic risk? (English)

1 reference

17 August 2017

Wasim Haque

1 reference

17 August 2017

Jawed Fareed

series ordinal

1 reference

17 August 2017

William H Wehrmacher

series ordinal

1 reference

17 August 2017

Harry L Messmore

series ordinal

1 reference

17 August 2017

language of work or name

1 reference

1 January 2006

1 reference

17 August 2017

published in

Comprehensive Therapy

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

261-266

1 reference

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

COX-2 inhibitors and the heart: are all coxibs the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Failing the public health--rofecoxib, Merck, and the FDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Time-to-Event Analyses for Long-Term Treatments — The APPROVe Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Cyclooxygenases: structural, cellular, and molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Prostaglandins and leukotrienes: advances in eicosanoid biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Mechanism of action of aspirin-like drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Blood pressure effects of COX-2 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

NO-aspirins: a class of new anti-inflammatory and antithrombotic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02698073

21 January 2018

Identifiers

DOI

10.1007/BF02698073

1 reference

17 August 2017

1 reference